20.109(F12) Pre-Proposal: Engineering Viral Magnetic Nanoparticles for Magnetic Hyperthermic Cancer Therapy - Revision history

Coyin Oh at 19:57, 29 November 2012

Coyin Oh — Thu, 29 Nov 2012 19:57:08 GMT

←Older revision		Revision as of 19:57, 29 November 2012
Line 38:		Line 38:
	<br/>		<br/>

-	Currently, the greatest efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Our hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the ~~45-80~~% range.	+	Currently, the greatest efficacy of magnetic hyperthermia is approximately 1% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Our hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 5% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Coyin Oh: /* Introduction */

Coyin Oh — Thu, 29 Nov 2012 11:47:54 GMT

Introduction

←Older revision		Revision as of 11:47, 29 November 2012
Line 14:		Line 14:
	==Introduction==		==Introduction==

-	The field of magnetic hyperthermia has attracted a lot of attention in the past thirty years as an alternative cancer therapy method. Magnetic hyperthermia proposes the placement of magnetic nanoparticles (MNP) in tumor cells under an alternating magnetic field. Nanoparticles often have unique physical and chemical properties that can be varied based on size and shape. MNPs are no different; these nanoparticles are superparamagnetic, gaining magnetic properties in the presence of a magnetic field. As the direction of the magnetic field alternates, MNPs undergo magnetic hysteresis losses that are dissipated to local surroundings as thermal energy. Targeted sites are usually heated to temperatures between 42 and 45 C to cause cell damage or death. A ~~mean~~ challenge with magnetic hyperthermia is the localization of MNPs to targeted tumor cells. It is possible for MNPs to circulate through the bloodstream and not reach the intended targeted sites. In addition, they at times are internalized and absorbed by the endoplasmic reticulum system of the cells. ~~<ref> Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17 </ref>~~ This low efficiency of MNP transport calls for a higher applied dosage of MNPs. How can we concentrate MNPs within tumor cells to produce sufficient heat for complete cell apoptosis?	+	The field of magnetic hyperthermia has attracted a lot of attention in the past thirty years as an alternative cancer therapy method. Magnetic hyperthermia proposes the placement of magnetic nanoparticles (MNP) in tumor cells under an alternating magnetic field. Nanoparticles often have unique physical and chemical properties that can be varied based on size and shape. MNPs are no different; these nanoparticles are superparamagnetic, gaining magnetic properties in the presence of a magnetic field. As the direction of the magnetic field alternates, MNPs undergo magnetic hysteresis losses that are dissipated to local surroundings as thermal energy [1]. Targeted sites are usually heated to temperatures between 42 and 45 C to cause cell damage or death [2]. A major challenge with magnetic hyperthermia is the localization of MNPs to targeted tumor cells. It is possible for MNPs to circulate through the bloodstream and not reach the intended targeted sites. In addition, they at times are internalized and absorbed by the endoplasmic reticulum system of the cells. This low efficiency of MNP transport calls for a higher applied dosage of MNPs [3]. How can we concentrate MNPs within tumor cells to produce sufficient heat for complete cell apoptosis?
	<br/><br/>		<br/><br/>
	'''References:'''		'''References:'''
-	~~{{Reflist}}~~
-	~~# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.~~
	# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.		# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.
		+	# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.
	# Bakoglidis KD, Simeonidis K, Sakellari D, Stefanou G, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics 2012; 48:1320-1323.		# Bakoglidis KD, Simeonidis K, Sakellari D, Stefanou G, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics 2012; 48:1320-1323.

Joanna Yeh: /* Your idea */

Joanna Yeh — Thu, 29 Nov 2012 11:46:36 GMT

Your idea

←Older revision		Revision as of 11:46, 29 November 2012
Line 39:		Line 39:
	<br/>		<br/>

-	Currently, the greatest efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. ~~Out~~ hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 45-80% range.	+	Currently, the greatest efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Our hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 45-80% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Joanna Yeh: /* Your idea */

Joanna Yeh — Thu, 29 Nov 2012 11:46:09 GMT

Your idea

←Older revision		Revision as of 11:46, 29 November 2012
Line 39:		Line 39:
	<br/>		<br/>

-	Currently, the ~~best~~ efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Out hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 45-80% range.	+	Currently, the greatest efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Out hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 45-80% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Joanna Yeh: /* Your idea */

Joanna Yeh — Thu, 29 Nov 2012 11:45:19 GMT

Your idea

←Older revision		Revision as of 11:45, 29 November 2012
Line 39:		Line 39:
	<br/>		<br/>

-	Currently, the best efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Out hope is that our engineered viral particle will be capable of achieving similar, if not higher, efficacy, preferably in the 45-80% range.	+	Currently, the best efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Out hope is that our engineered viral particle will be capable of achieving similar if not higher efficacy, preferably in the 45-80% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Joanna Yeh: /* Your idea */

Joanna Yeh — Thu, 29 Nov 2012 11:45:01 GMT

Your idea

←Older revision		Revision as of 11:45, 29 November 2012
Line 39:		Line 39:
	<br/>		<br/>

-	~~So far~~, the ~~current~~ best efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when ~~this is~~ aided by a 10Gy radiation. ~~We are hoping~~ that our engineered viral particle ~~can achieve an efficacy~~ of similar ~~level~~, if not higher, preferably in the 45-80% range.	+	Currently, the best efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when aided by a 10Gy radiation. Out hope is that our engineered viral particle will be capable of achieving similar, if not higher, efficacy, preferably in the 45-80% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Coyin Oh: /* Introduction */

Coyin Oh — Thu, 29 Nov 2012 11:43:31 GMT

Introduction

←Older revision		Revision as of 11:43, 29 November 2012
Line 14:		Line 14:
	==Introduction==		==Introduction==

-	The field of magnetic hyperthermia has attracted a lot of attention in the past thirty years as an alternative cancer therapy method. Magnetic hyperthermia proposes the placement of magnetic nanoparticles (MNP) in tumor cells under an alternating magnetic field. Nanoparticles often have unique physical and chemical properties that can be varied based on size and shape. MNPs are no different; these nanoparticles are superparamagnetic, gaining magnetic properties in the presence of a magnetic field. As the direction of the magnetic field alternates, MNPs undergo magnetic hysteresis losses that are dissipated to local surroundings as thermal energy. Targeted sites are usually heated to temperatures between 42 and 45 C to cause cell damage or death. A mean challenge with magnetic hyperthermia is the localization of MNPs to targeted tumor cells. It is possible for MNPs to circulate through the bloodstream and not reach the intended targeted sites. In addition, they at times are internalized and absorbed by the endoplasmic reticulum system of the cells. This low efficiency of MNP transport calls for a higher applied dosage of MNPs. How can we concentrate MNPs within tumor cells to produce sufficient heat for complete cell apoptosis?	+	The field of magnetic hyperthermia has attracted a lot of attention in the past thirty years as an alternative cancer therapy method. Magnetic hyperthermia proposes the placement of magnetic nanoparticles (MNP) in tumor cells under an alternating magnetic field. Nanoparticles often have unique physical and chemical properties that can be varied based on size and shape. MNPs are no different; these nanoparticles are superparamagnetic, gaining magnetic properties in the presence of a magnetic field. As the direction of the magnetic field alternates, MNPs undergo magnetic hysteresis losses that are dissipated to local surroundings as thermal energy. Targeted sites are usually heated to temperatures between 42 and 45 C to cause cell damage or death. A mean challenge with magnetic hyperthermia is the localization of MNPs to targeted tumor cells. It is possible for MNPs to circulate through the bloodstream and not reach the intended targeted sites. In addition, they at times are internalized and absorbed by the endoplasmic reticulum system of the cells. <ref> Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17 </ref> This low efficiency of MNP transport calls for a higher applied dosage of MNPs. How can we concentrate MNPs within tumor cells to produce sufficient heat for complete cell apoptosis?
	<br/><br/>		<br/><br/>
	'''References:'''		'''References:'''
		+	{{Reflist}}
	# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.		# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.
	# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.		# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.

Joanna Yeh: /* Introduction */

Joanna Yeh — Thu, 29 Nov 2012 11:41:42 GMT

Introduction

←Older revision		Revision as of 11:41, 29 November 2012
Line 17:		Line 17:
	<br/><br/>		<br/><br/>
	'''References:'''		'''References:'''
-	# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.	+	# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, and Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.
	# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.		# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.
-	# Bakoglidis KD, Simeonidis K, Sakellari D, G. Stefanou, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics 2012; 48:1320-1323.	+	# Bakoglidis KD, Simeonidis K, Sakellari D, Stefanou G, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics 2012; 48:1320-1323.

	==Your idea==		==Your idea==

Coyin Oh: /* Your idea */

Coyin Oh — Thu, 29 Nov 2012 11:40:39 GMT

Your idea

←Older revision		Revision as of 11:40, 29 November 2012
Line 37:		Line 37:
	:Perform an ''in vivo'' experiment by injecting the engineered viral MNPs into the circulatory system of mice that have developed tumors. By subjecting these mice to an alternating magnetic field under standard hyperthermia conditions and measuring the change in tumor size, we will be able to quantify the efficacy of using viral MNPs in magnetic hyperthermia.<br/>		:Perform an ''in vivo'' experiment by injecting the engineered viral MNPs into the circulatory system of mice that have developed tumors. By subjecting these mice to an alternating magnetic field under standard hyperthermia conditions and measuring the change in tumor size, we will be able to quantify the efficacy of using viral MNPs in magnetic hyperthermia.<br/>
	<br/>		<br/>
		+
		+	So far, the current best efficacy of magnetic hyperthermia is approximately 60% (mass of MNP accumulated in tumor cells / mass of MNP injected into the body), as demonstrated by the Hoopes group when this is aided by a 10Gy radiation. We are hoping that our engineered viral particle can achieve an efficacy of similar level, if not higher, preferably in the 45-80% range.

	== A sketch ==		== A sketch ==
	[[Image:update flow.png\|thumb\|center\|600px]]		[[Image:update flow.png\|thumb\|center\|600px]]

Joanna Yeh: /* Introduction */

Joanna Yeh — Thu, 29 Nov 2012 11:40:39 GMT

Introduction

←Older revision		Revision as of 11:40, 29 November 2012
Line 17:		Line 17:
	<br/><br/>		<br/><br/>
	'''References:'''		'''References:'''
-	# ~~A.J.~~ Giustini, ~~A.A.~~ Petryk, ~~S.M.~~ Cassim, ~~J.A.~~ Tate, I. Baker, ~~P.J.~~ Hoopes. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.	+	# Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano LIFE 2010; 01: 17.
	# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.		# Gupta AK, Naregalkar RR, Vaidya VD, and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Future Medicine 2007; 2(1): 23-39.
-	# Bakoglidis KD, Simeonidis K, Sakellari D, G. Stefanou, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics. 2012; 48:1320-1323.	+	# Bakoglidis KD, Simeonidis K, Sakellari D, G. Stefanou, and Angelakeris M. Size-Dependent Mechanisms in AC Magnetic Hyperthermia Response of Iron-Oxide Nanoparticles. IEEE Transactions on Magnetics 2012; 48:1320-1323.

	==Your idea==		==Your idea==